Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia

被引:92
|
作者
Ryan, Michael B. [1 ,2 ,3 ]
Bair-Marshall, Chloe [4 ]
Nelson, Alexandra B. [1 ,2 ,3 ,4 ]
机构
[1] UCSF, Neurosci Grad Program, San Francisco, CA 94158 USA
[2] UCSF, Weill Inst Neurosci, San Francisco, CA 94158 USA
[3] UCSF, Kavli Inst Fundamental Neurosci, San Francisco, CA 94158 USA
[4] UCSF, Dept Neurol, San Francisco, CA 94158 USA
来源
CELL REPORTS | 2018年 / 23卷 / 12期
关键词
DOPA-INDUCED DYSKINESIA; MEDIUM SPINY NEURONS; PROJECTION NEURONS; SUBTHALAMIC NUCLEUS; CRE-RECOMBINASE; DISEASE; ACTIVATION; APOMORPHINE; RECORDINGS; PLASTICITY;
D O I
10.1016/j.celrep.2018.05.059
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Action selection relies on the coordinated activity of striatel direct and indirect pathway medium spiny neurons (dMSNs and iMSNs, respectively). Loss of dopamine in Parkinson's disease is thought to disrupt this balance. While dopamine replacement with levodopa may restore normal function, the development of involuntary movements (levodopa-induced dyskinesia [LID]) limits therapy. How chronic dopamine loss and replacement with levodopa modulate the firing of identified MSNs in behaving animals is unknown. Using optogenetically labeled striatel single-unit recordings, we assess circuit dysfunction in parkinsonism and LID. Counter to current models, we found that following dopamine depletion, iMSN firing was elevated only during periods of immobility, while dMSN firing was dramatically and persistently reduced. Most notably, we identified a subpopulation of dMSNs with abnormally high levodopa-evoked firing rates, which correlated specifically with dyskinesia. These findings provide key insights into the circuit mechanisms underlying parkinsonism and LID, with implications for developing targeted therapies.
引用
收藏
页码:3438 / +
页数:14
相关论文
共 50 条
  • [41] Risk factors for the development of levodopa-induced dyskinesia
    Schaeffer, E.
    Huber, H.
    Liepelt-Scarfone, I.
    Berg, D.
    MOVEMENT DISORDERS, 2012, 27 : S137 - S138
  • [42] LEVODOPA-INDUCED DYSKINESIA - REVIEW, OBSERVATIONS, AND SPECULATIONS
    NUTT, JG
    NEUROLOGY, 1990, 40 (02) : 340 - 345
  • [43] Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
    Zheng, Chang-Qing
    Fan, Hong-Xia
    Li, Xiao-Xian
    Li, Jing-Jie
    Sheng, Shuo
    Zhang, Feng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [44] Dysregulation of BET proteins in levodopa-induced dyskinesia
    Figge, David A.
    Standaert, David G.
    NEUROBIOLOGY OF DISEASE, 2017, 102 : 125 - 132
  • [45] Measurement of Levodopa-Induced Dyskinesia with Inertial Sensors
    Chung, Kathryn A.
    El-Gohary, Mahmoud
    Lobb, Brenna M.
    McNames, James
    NEUROLOGY, 2009, 72 (11) : A65 - A65
  • [46] Clinical Aspects and Management of Levodopa-Induced Dyskinesia
    Tambasco, Nicola
    Simoni, Simone
    Marsili, Erica
    Sacchini, Elisa
    Murasecco, Donatella
    Cardaioli, Gabriela
    Rossi, Aroldo
    Calabresi, Paolo
    PARKINSONS DISEASE, 2012, 2012
  • [47] Molecular mechanisms underlying levodopa-induced dyskinesia
    Calabresi, Paolo
    Di Filippo, Massimiliano
    Ghiglieri, Veronica
    Picconi, Barbara
    MOVEMENT DISORDERS, 2008, 23 : S570 - S579
  • [48] Levodopa-induced dyskinesia in Parkinson’s disease
    J. M. Brotchie
    J. Lee
    K. Venderova
    Journal of Neural Transmission, 2005, 112 : 359 - 391
  • [49] Levodopa-Induced Dyskinesia: "TRAP"ping the Culprit
    Prasad, Shweta
    Pal, Pramod Kumar
    MOVEMENT DISORDERS, 2018, 33 (05) : 761 - 761